ATE332967T1 - Antisense oligonukleotide zur hemmung der expression der integrin alphav untereinheit - Google Patents

Antisense oligonukleotide zur hemmung der expression der integrin alphav untereinheit

Info

Publication number
ATE332967T1
ATE332967T1 AT99920590T AT99920590T ATE332967T1 AT E332967 T1 ATE332967 T1 AT E332967T1 AT 99920590 T AT99920590 T AT 99920590T AT 99920590 T AT99920590 T AT 99920590T AT E332967 T1 ATE332967 T1 AT E332967T1
Authority
AT
Austria
Prior art keywords
inhibiting
expression
antisense oligonucleotides
integrin alphav
subunit
Prior art date
Application number
AT99920590T
Other languages
English (en)
Inventor
Eugen Uhlmann
Anuschirwan Peyman
Anna Maria Teti
Ida Villanova
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of ATE332967T1 publication Critical patent/ATE332967T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3535—Nitrogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT99920590T 1998-04-17 1999-04-01 Antisense oligonukleotide zur hemmung der expression der integrin alphav untereinheit ATE332967T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98106989A EP0950709A1 (de) 1998-04-17 1998-04-17 Antisense Oligonukleotide zur Hemmung der Expression der Integrin alphaV Untereinheit

Publications (1)

Publication Number Publication Date
ATE332967T1 true ATE332967T1 (de) 2006-08-15

Family

ID=8231774

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99920590T ATE332967T1 (de) 1998-04-17 1999-04-01 Antisense oligonukleotide zur hemmung der expression der integrin alphav untereinheit

Country Status (9)

Country Link
EP (2) EP0950709A1 (de)
JP (1) JP2002512025A (de)
KR (1) KR100688045B1 (de)
AT (1) ATE332967T1 (de)
AU (1) AU3812599A (de)
BR (1) BR9909700A (de)
CA (1) CA2325821A1 (de)
DE (1) DE69932331D1 (de)
WO (1) WO1999054456A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE453667T1 (de) * 1998-10-16 2010-01-15 Otsuka Pharma Co Ltd Neovaskular-spezifische peptide
US20040102406A1 (en) * 2000-06-29 2004-05-27 Pnina Brodt Antisense oligonucleotides to inhibit angiogenesis and/or metastasis
EP1197553A1 (de) * 2000-10-12 2002-04-17 A3D GmbH, Antisense Design & Drug Development Antisense-Nukleinsäure gegen das alphaV Integrin
US7829087B2 (en) * 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
EP1642585A1 (de) * 2004-09-27 2006-04-05 Immunotech S.A. Osteogene Oligonukleotide und deren Verwendungen
TW200950824A (en) 2008-04-30 2009-12-16 Kci Licensing Inc Use of nucleic acids with reduced pressure therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4338704A1 (de) * 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung

Also Published As

Publication number Publication date
EP0950709A1 (de) 1999-10-20
JP2002512025A (ja) 2002-04-23
EP1071764A1 (de) 2001-01-31
AU3812599A (en) 1999-11-08
EP1071764B1 (de) 2006-07-12
BR9909700A (pt) 2000-12-26
CA2325821A1 (en) 1999-10-28
DE69932331D1 (de) 2006-08-24
KR100688045B1 (ko) 2007-02-28
WO1999054456A1 (en) 1999-10-28
KR20010042796A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
PT731835E (pt) Oligonucleotidos anti-sentido possuindo actividade inibidora de tumorigenicidade
DE50214715D1 (de) Synthetische doppelsträngige oligonucleotide zur gezielten hemmung der genexpression
WO2003023005A3 (en) Antisense modulation of pka regulatory subunit rii alpha expression
DE69403642D1 (de) 7-deazapurin modifizierte oligonukleotide
EP1009860A4 (de) Antisense oligonukleotid zur inhibierung von ras
WO2001047944A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
EP1189918A4 (de) Antisense-modulation der integrin-beta-3-expression
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
DK1123414T3 (da) Antisense-modulering af integrin alpha 4.ekspression
WO2000029623A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
ATE332967T1 (de) Antisense oligonukleotide zur hemmung der expression der integrin alphav untereinheit
WO2003057843A3 (en) Methods and materials for modulating trpc4
WO2002064737A3 (en) Antisense modulation of protein phosphatase 2 catalytic subunit beta expression
EP1248633A4 (de) Antisense-modulation der expression von glycogen-synthase kinase 3 beta
EP1448582A4 (de) Telomerase-interferenz
WO2003057847A8 (en) METHODS AND MATERIALS FOR MODULATING ENaC-BETA
EP1248635A4 (de) Antisense-modulation der glykogen-synthase-kinase-3alpha-expression
WO2001048245A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2001040521A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
ATE462791T1 (de) Parvovirus ns1 varianten
WO2001051670A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
DE60140552D1 (de) Transglutaminase genprodukte
BR0016347A (pt) Oligonucleotìdios antisenso
WO2000029622A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2003057898A8 (en) Methods and materials for modulating p2x2

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties